Evidence map›Paper›PMID 41557057›Full record

ArticleMolecular neurobiology2026

Atractylenolide III Attenuated Neurotoxicity in Alzheimer's Disease via AMPK/GSK3β/Nrf2/HO-1 Signaling Pathway.

Zhiwei Xu, Shijie Dai, Yangsheng Wu, Yantao Zhu, Ping Qiu, Shan Xu, Fangjian Qiu, Xueqian Peng, Wenhong Liu, Hui Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhiwei Xu *Jinhua Academy, Zhejiang Chinese Medical University, Jinhua, Zhejiang, China.
Shijie Dai *School of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yangsheng Wu *School of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yantao ZhuJinhua Hospital of Traditional Chinese Medicine, Jinhua, Zhejiang, China.
Ping QiuSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Shan XuJinhua Hospital of Traditional Chinese Medicine, Jinhua, Zhejiang, China.
Fangjian QiuJinhua Hospital of Traditional Chinese Medicine, Jinhua, Zhejiang, China.
Xueqian PengJinhua Academy, Zhejiang Chinese Medical University, Jinhua, Zhejiang, China. xueqianpeng@zju.edu.cn.
Wenhong LiuSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. lwh@zcmu.edu.cn.
Hui WangJinhua Academy, Zhejiang Chinese Medical University, Jinhua, Zhejiang, China. wh@zcmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and widespread neuroinflammation. Atractylenolide III (AT-III), the primary active compound in Atractylodes macrocephala Koidz, has shown various health-promoting effects, including antioxidant properties and neuroprotection. However, the anti-AD molecular mechanism of AT-III remains to be further investigated. FAD

Indexed as

Alzheimer DiseaseAMP-Activated Protein KinasesGlycogen Synthase Kinase 3 betaHeme Oxygenase-1LactonesNF-E2-Related Factor 2SesquiterpenesSignal TransductionAmyloid beta-PeptidesAnimalsApoptosisCell Line, TumorHippocampusHumansMaleMiceAMP-Activated Protein KinasesAmyloid beta-Peptidesatractylenolide IIIGlycogen Synthase Kinase 3 betaHeme Oxygenase-1LactonesNeuroprotective AgentsNF-E2-Related Factor 2SesquiterpenesAlzheimer’s diseaseAMPKAtractylenolide IIIGSK3βHO-1 signaling pathwayNeurotoxicityNrf2

Identifiers

PMID41557057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.